New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT02321501
First seen Nov 10, 2025 · Last updated May 10, 2026 · Updated 25 times
Summary
This early-phase study tests the safety and best dose of combining two drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC). The goal is to find the highest dose that is safe and to see if the combination can slow cancer growth. About 37 adults whose cancer has spread or not responded to prior treatment will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.